Instil Bio Q2 net loss $3.24/share; cash $103.6M; IND cleared for '2510

Instil Bio, Inc.

2025-Q2 EPS reported -$7.55

Cash, equivalents, marketable securities and long-term investments of $103.6M as of June 30, 2025; funded beyond 2026.
Net loss per share $3.24 (GAAP) and $2.88 (non-GAAP) for Q2 2025, vs $2.29 and $1.57 year-ago.
R&D expenses $6.7M in Q2 2025; in-process R&D expenses $10.0M; G&A expenses $6.2M.
U.S. IND for AXN-2510/IMM2510 cleared; U.S. trial initiation expected before end of 2025.
Appointed Jamie Freedman, M.D., Ph.D. as Chief Medical Officer in June 2025.

item 2.02item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.